KR20010032779A - 비만 치료 방법 - Google Patents
비만 치료 방법 Download PDFInfo
- Publication number
- KR20010032779A KR20010032779A KR1020007006075A KR20007006075A KR20010032779A KR 20010032779 A KR20010032779 A KR 20010032779A KR 1020007006075 A KR1020007006075 A KR 1020007006075A KR 20007006075 A KR20007006075 A KR 20007006075A KR 20010032779 A KR20010032779 A KR 20010032779A
- Authority
- KR
- South Korea
- Prior art keywords
- obesity
- drugs
- endocelin
- med
- chem
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 13
- 235000020824 obesity Nutrition 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000002464 receptor antagonist Substances 0.000 claims abstract description 9
- 229940044551 receptor antagonist Drugs 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000007903 gelatin capsule Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 4
- 229940125833 compound 23 Drugs 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010047918 TAK 044 Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- UWHBIISPHYTOGL-PFSAEEMXSA-L disodium;2-[(2r,5s,8s,11s,14s,17r)-8-(carboxylatomethyl)-17-(1h-indol-3-ylmethyl)-14-(2-methylpropyl)-3,6,9,12,15,18-hexaoxo-5-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-11-thiophen-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]acetate Chemical compound [Na+].[Na+].C([C@H]1C(=O)N[C@@H](CC([O-])=O)C(=O)N[C@@H](C(=O)N[C@H](C(N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N1)=O)CC(C)C)C=1SC=CC=1)C(=O)N(CC1)CCN1C1=CC=CC=C1 UWHBIISPHYTOGL-PFSAEEMXSA-L 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- -1 invert sugar Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- LJGUZUROJOJEMI-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C(=CC=CC=2)C=2C=CC(=CC=2)C=2OC=CN=2)=C1C LJGUZUROJOJEMI-UHFFFAOYSA-N 0.000 description 1
- ORJRYNKVKJAJPY-UHFFFAOYSA-N n-[[2-[2-[(4,5-dimethyl-1,2-oxazol-3-yl)sulfamoyl]phenyl]-5-(1,3-oxazol-2-yl)phenyl]methyl]-n,3,3-trimethylbutanamide Chemical compound CC(C)(C)CC(=O)N(C)CC1=CC(C=2OC=CN=2)=CC=C1C1=CC=CC=C1S(=O)(=O)NC1=NOC(C)=C1C ORJRYNKVKJAJPY-UHFFFAOYSA-N 0.000 description 1
- 229940124706 obesity therapeutics Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000011303 renal artery atheroma Diseases 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- COKFAUSKNMGISZ-BMGIYVBOSA-M sodium;(z)-2-(2,1,3-benzothiadiazol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-[(3,4,5-trimethoxyphenyl)methyl]but-2-enoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)C(\CC=1C=C(OC)C(OC)=C(OC)C=1)=C(/C([O-])=O)C1=CC2=NSN=C2C=C1 COKFAUSKNMGISZ-BMGIYVBOSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 비만 또는 비만에 의해 유발되는 질병을 치료하는 약물 제조를 위한 엔도셀린 수용체 길항제의 용도에 관한 것이다.
Description
본 발명은 비만 및 비만으로 인한 질병을 제어하는 방법에 관한 것이다.
펩티드 호르몬인 엔도셀린은 그의 강한 혈관 수축 특성으로 알려져있다. 따라서 엔도셀린 수용체 길항제는 주로 심혈관계 병리에서 시험되고 있다.
본 발명은 비만 및 비만으로 인한 질병을 제어하는 약물을 제조하기 위한 엔도셀린 수용체 길항제의 용도에 관한 것이다.
엔도셀린A및 혼합된 엔도셀린A/B수용체 길항제 모두가 사용될 수 있다.
특히 적합한 엔도셀린 수용체 길항제는 하기와 같다.
1. TBC-11251 (J. Med. Chem., 40, No. 11, 1690-97, 1997),
2. BMS-193884 (EP 558,258),
3. BMS-207940 (Pharmaprojects (13. 06. 97)),
4. BQ-123 (Exp. Opin. Invest. Drugs, 1997, 6, No. 5, 475-487),
5. SB-209670 (Exp. Opin. Invest. Drugs, 1997, 6, No. 5, 475-487),
6. SB-217242 (Exp. Opin. Invest. Drugs, 1997, 6, No. 5, 475-487),
7. SB-209598 (Trends in Pharmacol. Sci., 17, 177-81, 1996),
8. TAK-044 (Exp. Opin. Invest. Drugs, 1997, 6, No. 5, 475-487),
9. Bosentan (Trends in Pharmacol. Sci., 18, 408-12, 1997),
10. PD-156707 (J. Med. Chem., 40, No. 7, 1063-74, 1997),
11. L-749327 (Bioorg. Med. Chem. Lett., 7, No. 3, 275-280, 1997),
12. L-754142 (Exp. Opin. Invest. Drugs, 1997, 6, No. 5, 475-487),
13. ABT-627 (J. Med. Chem., 40, No. 20, 3217-27, 1997),
14. A-127772 (J. Med. Chem., 39, No. 5, 1039-1048, 1996),
15. A-206377 (213thAmerican Chemical Society National Meeting, San Francisco, California, USA, 13-17 April, 1997, Poster, MEDI 193),
16. A-182086 (J. Med. Chem., 40, No. 20, 3217-27, 1997),
17. EMD-93246 (211thAmerican Chemical Society National Meeting, New Orleans, USA, 1996, Poster, MEDI 143),
18. EMD-122801 (Bioorg. Med. Chem. Lett., 8, No. 1, 17-22, 1998),
19. ZD-1611 (Trends in Pharmacol. Sci., 18, 408-12, 1997),
20. AC-610612 (R ＆ D Focus Drug News (18. 05. 98)),
21. T-0201 (70th Annual Meeting of the Japanese Pharmacological Society, Chiba, Japan, 22-25 March 1997, Lecture, O-133), 및
22. J-104132 (R ＆ D Focus Drug News (15. 12. 97)).
특히 비만이란 체중이 정상 체중을 20%이상 초과할 때 사용되는 용어이다. 비만의 원인은 과식 또는 예를 들어 유전적 고콜레스테롤혈증과 같은 음식의 잘못된 이용 때문이다. 비만에 의해 또는 종종 비만과 관련되어 유발되는 질병으로는 특히 고혈압, 타입 2 당뇨병, 고지혈증, 만성 신부전 및 아테롬성 동맥경화증이 있으며 또한 요산증도 가능하다.
지금까지 동물 실험에 있어서 비만의 병리 상태를 모사하기는 매우 어려웠다(극히 과량의 콜레스테롤 투여). 그러나, 최근에 아포지단백질 E에 대한유전자가 결핍된 마우스가 개량되어 이를 비만 치료 물질 시험에 사용할 수 있게 되었다.
엔도셀린 수용체 길항물질 23의 효과는 apoE에 대한 유전자가 결핍된 상기 마우스의 동물 모델로 조사하였다. 대조 래트에서 예측한대로 고지방 규정식을 섭취하는 동물의 체중은 크게 증가하였다. 이는 간의 지방 분해화 함께 간의 크기 증가와 관련된다. 대등한 군에서, 시험 동물을 물질 23(50mg/kg/일)으로 처리하였다. 이 군에서 체중 및 간의 중량의 증가는 완벽하게 방지되었다. 또한 간은 조직학적으로 특이성을 보이지 않았다.
엔도셀린A및 엔도셀린A/B수용체 길항제는 일생동안 투여되어야 하며, 그 투여량은 50 내지 500mg/환자/일이다.
엔도셀린A및 엔도셀린A/B수용체 길항제는 예를 들어 비코팅, 코팅 또는 당의정, 경질 및 연질 젤라틴 캅셀, 용액, 유화액 및 현탁액의 형태로 일반적으로 경구로 투여된다. 그러나 또한 예를 들어 좌제 형태로서 직장으로, 또는 예를 들어 주사액제 형태로서 비경구로 투여될 수도 있다.
비코팅, 코팅 및 당의정 및 경질 젤라틴 캅셀을 제조하기 위해, 본 발명에 따른 조합물을 제약상 불활성인 무기 또는 유기 부형제로 가공할 수 있다. 비코팅 및 당의정 및 경질 젤라틴 캅셀에 사용할 수 있는 이런 종류의 부형제는 락토오스, 옥수수 전분 또는 그의 유도체, 탈크, 스테아르 산 또는 그의 염이 있다. 연질 젤라틴 캅셀에 적합한 부형제는 식물성유, 왁스, 지방, 반고상 또는 액상 폴리올이다.
용액제 및 시럽제를 제조하는데 적합한 부형제는 예를 들어 물, 폴리올, 수크로오스, 전화당, 포도당 등이다. 주사용제에 적합한 부형제는 물, 알콜, 폴리올, 글리세롤, 식물성유이다. 좌제에 적합한 부형제는 천연 또는 경화유, 왁스, 지방, 반고상 또는 액상 폴리올 등이다.
또한 제약 제제는 방부제, 용해제, 안정화제, 습윤제, 유화제, 감미제, 착색제, 방향제, 삼투압을 바꾸기 위한 염, 완충제, 코팅제 및(또는) 항산화제를 추가로 함유할 수도 있다.
하기의 실시예는 본 발명을 설명한다.
〈실시예 1〉
하기의 조성을 갖는 코팅정을 제조하였다:
화합물 23 300.0mg
무수락토오스 30.0mg
미세결정형 셀룰로오스 30.0mg
폴리비닐피롤리돈 20.0mg
마그네슘 스테아레이트 5.0mg
폴리에틸렌 글리콜 6000 0.8mg
황색 산화아연 1.2mg
이산화티타늄 0.3mg
탈크 0.7mg
화합물 23, 락토오스, 셀룰로오스 및 폴리비닐피롤리돈을 습윤 과립화하고 건조하였다. 체로 거른 과립을 마그네슘 스테아레이트와 혼합하고, 그 혼합물을 각 390.0mg의 무게의 타원형 정제핵으로 압착하였다. 이후 핵을 코팅정의 최종 무게가 400mg이 될 때까지 코팅하였다.
〈실시예 2〉
300mg의 화합물 23 대신 화합물 26을 300mg 함유하는 코팅정을 실시예 1에서와 유사한 방법으로 제조하였다.
〈실시예 3〉
하기의 조성을 가지는 경질 젤라틴 캅셀의 제조:
화합물 23 250.0mg
결정형 락토오스 18.0mg
폴리비닐피롤리돈 15.0mg
미세결정형 셀룰로오스 17.5mg
소듐 카르복실메틸 전분 10.0mg
탈크 0.7mg
마그네슘 스테아레이트 3.0mg
상위의 5개 물질을 습윤 과립화하여 건조하였다. 과립을 소듐 카르복실메틸 전분, 탈크 및 마그네슘 스테아레이트와 혼합하고, 혼합물을 크기 0의 경질 젤라틴 캅셀로 패킹하였다.
Claims (1)
- 비만 및 비만에 의해 유발되는 질병을 조절하는 약물을 제조하기 위한 엔도셀린 수용체 길항제의 용도.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19754082.1 | 1997-12-05 | ||
| DE19754082A DE19754082A1 (de) | 1997-12-05 | 1997-12-05 | Methode zur Bekämpfung der Fettleibigkeit |
| PCT/EP1998/007501 WO1999029308A2 (de) | 1997-12-05 | 1998-11-21 | Methode zur bekämpfung der fettleibigkeit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010032779A true KR20010032779A (ko) | 2001-04-25 |
Family
ID=7850913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007006075A KR20010032779A (ko) | 1997-12-05 | 1998-11-21 | 비만 치료 방법 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6197780B1 (ko) |
| EP (1) | EP1035851B1 (ko) |
| JP (1) | JP2002512173A (ko) |
| KR (1) | KR20010032779A (ko) |
| CN (1) | CN1152685C (ko) |
| AT (1) | ATE204172T1 (ko) |
| AU (1) | AU751053B2 (ko) |
| BR (1) | BR9815335A (ko) |
| CA (1) | CA2311423C (ko) |
| CZ (1) | CZ300442B6 (ko) |
| DE (2) | DE19754082A1 (ko) |
| ES (1) | ES2162493T3 (ko) |
| HK (1) | HK1037141A1 (ko) |
| HU (1) | HUP0100171A3 (ko) |
| NO (2) | NO324694B1 (ko) |
| RU (1) | RU2292891C2 (ko) |
| WO (1) | WO1999029308A2 (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| EP1130027A1 (de) * | 2000-02-29 | 2001-09-05 | Aventis Pharma Deutschland GmbH | Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben |
| US20050175667A1 (en) * | 2004-02-10 | 2005-08-11 | Wenda Carlyle | Use of endothelin antagonists to prevent restenosis |
| CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| SI2776038T1 (en) * | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | ACC INHIBITORS AND THEIR USE |
| WO2016099233A2 (ru) * | 2014-10-20 | 2016-06-23 | Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" | Фармацевтическая композиция для лечения туберкулеза |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| HUE053175T2 (hu) | 2015-11-25 | 2021-06-28 | Gilead Apollo Llc | ACC-gátló észterek és azok alkalmazása |
| CA3004747A1 (en) | 2015-11-25 | 2017-06-01 | Gilead Apollo, Llc | Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidine |
| ES2939977T3 (es) | 2015-11-25 | 2023-04-28 | Gilead Apollo Llc | Inhibidores de triazol ACC y usos de los mismos |
| EP3380480B1 (en) | 2015-11-25 | 2022-12-14 | Gilead Apollo, LLC | Pyrazole acc inhibitors and uses thereof |
| CA3155220C (en) | 2016-03-02 | 2024-01-16 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0670320A4 (en) * | 1992-12-01 | 1997-05-02 | Green Cross Corp | DERIVATIVE OF 1,8-NAPHTHYRIDIN-2-ONE AND USE OF THIS DERIVATIVE. |
| AU6603996A (en) * | 1995-08-24 | 1997-03-19 | Warner-Lambert Company | Furanone endothelin antagonists |
| JP3116347B2 (ja) * | 1996-11-13 | 2000-12-11 | 田辺製薬株式会社 | 医薬組成物 |
-
1997
- 1997-12-05 DE DE19754082A patent/DE19754082A1/de not_active Withdrawn
-
1998
- 1998-11-21 ES ES98965685T patent/ES2162493T3/es not_active Expired - Lifetime
- 1998-11-21 US US09/530,131 patent/US6197780B1/en not_active Expired - Lifetime
- 1998-11-21 CA CA002311423A patent/CA2311423C/en not_active Expired - Fee Related
- 1998-11-21 WO PCT/EP1998/007501 patent/WO1999029308A2/de not_active Application Discontinuation
- 1998-11-21 CN CNB988118327A patent/CN1152685C/zh not_active Expired - Fee Related
- 1998-11-21 AU AU21535/99A patent/AU751053B2/en not_active Ceased
- 1998-11-21 EP EP98965685A patent/EP1035851B1/de not_active Expired - Lifetime
- 1998-11-21 DE DE59801230T patent/DE59801230D1/de not_active Expired - Lifetime
- 1998-11-21 KR KR1020007006075A patent/KR20010032779A/ko not_active Application Discontinuation
- 1998-11-21 JP JP2000523980A patent/JP2002512173A/ja active Pending
- 1998-11-21 HU HU0100171A patent/HUP0100171A3/hu unknown
- 1998-11-21 AT AT98965685T patent/ATE204172T1/de active
- 1998-11-21 BR BR9815335-8A patent/BR9815335A/pt not_active Application Discontinuation
- 1998-11-21 CZ CZ20002006A patent/CZ300442B6/cs not_active IP Right Cessation
-
2000
- 2000-05-30 NO NO20002777A patent/NO324694B1/no not_active IP Right Cessation
-
2001
- 2001-11-09 HK HK01107896A patent/HK1037141A1/xx not_active IP Right Cessation
-
2003
- 2003-12-29 RU RU2003138080/15A patent/RU2292891C2/ru not_active IP Right Cessation
-
2007
- 2007-08-30 NO NO20074419A patent/NO20074419L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20002777D0 (no) | 2000-05-30 |
| CN1152685C (zh) | 2004-06-09 |
| ES2162493T3 (es) | 2001-12-16 |
| CZ300442B6 (cs) | 2009-05-20 |
| EP1035851A2 (de) | 2000-09-20 |
| EP1035851B1 (de) | 2001-08-16 |
| RU2003138080A (ru) | 2005-06-10 |
| CN1301162A (zh) | 2001-06-27 |
| NO20074419L (no) | 2000-06-02 |
| CA2311423C (en) | 2008-01-29 |
| AU2153599A (en) | 1999-06-28 |
| HUP0100171A3 (en) | 2003-10-28 |
| BR9815335A (pt) | 2000-10-17 |
| DE59801230D1 (de) | 2001-09-20 |
| RU2292891C2 (ru) | 2007-02-10 |
| CA2311423A1 (en) | 1999-06-17 |
| JP2002512173A (ja) | 2002-04-23 |
| NO324694B1 (no) | 2007-12-03 |
| US6197780B1 (en) | 2001-03-06 |
| CZ20002006A3 (cs) | 2000-11-15 |
| DE19754082A1 (de) | 1999-06-10 |
| HUP0100171A2 (hu) | 2003-02-28 |
| ATE204172T1 (de) | 2001-09-15 |
| AU751053B2 (en) | 2002-08-08 |
| WO1999029308A2 (de) | 1999-06-17 |
| WO1999029308A3 (de) | 1999-09-30 |
| HK1037141A1 (en) | 2002-02-01 |
| NO20002777L (no) | 2000-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2211845B1 (en) | Glucocorticoid receptor antagonists such as mifepristone for treating cushing's syndrome | |
| KR101607081B1 (ko) | 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약 | |
| AU781827B2 (en) | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation | |
| TWI287448B (en) | A kit or pharmaceutical combination for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia in mammals | |
| KR20010032779A (ko) | 비만 치료 방법 | |
| US5990159A (en) | Use of 5HT4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors | |
| CA2263163A1 (en) | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists | |
| EP2029124A1 (en) | Use of gpcr agonists to delay progression of diabetes | |
| US20060035844A1 (en) | Preventive or remedy for diseases caused by hyperglycemia | |
| WO2007048332A1 (fr) | Composition pharmaceutique pour le traitement de la goutte et sa preparation et son utilisation | |
| AU781828B2 (en) | Dosing regimens for lasofoxifene | |
| EP1919472B1 (en) | Compositions and methods for treatment and prevention of hyperuricemia related health consequences | |
| CN103813792B (zh) | 用于治疗膀胱过度活动症的索利那新和唾液刺激剂的组合 | |
| CN101757627A (zh) | 用于治疗糖尿病的联合用药及药物组合物 | |
| MXPA00004989A (en) | Method for combating obesity | |
| JP4737686B2 (ja) | 新しい医薬 | |
| JP2008255008A (ja) | 滑膜細胞増殖抑制剤 | |
| Suh et al. | Pharmacokinetics and pharmacodynamics of azosemide | |
| Aschner | Canagliflozin for the treatment of adults with Type 2 diabetes | |
| KR20060097025A (ko) | Ａｔ１-길항제, 아밀로라이드 또는 트리아메테린, 및이뇨제의 배합물 | |
| Tablets et al. | PrJAMP Pioglitazone | |
| EP0005733A1 (en) | Pharmaceutical compositions for use in the treatment of diabetic nephropathy and method for preparing them | |
| Agent | PrACH-Pioglitazone | |
| WO2004002474A1 (ja) | 糖尿病性合併症の予防又は進展阻止用医薬組成物 | |
| WO2008026668A1 (fr) | Composition médicale contenant un agent d'amélioration de la résistance à l'insuline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| N231 | Notification of change of applicant | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| J201 | Request for trial against refusal decision | ||
| AMND | Amendment | ||
| B601 | Maintenance of original decision after re-examination before a trial | ||
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060605 Effective date: 20070424 Free format text: TRIAL NUMBER: 2006101004783; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060605 Effective date: 20070424 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: TRIAL NUMBER: 2007201004748; APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
| WITB | Written withdrawal of application | ||
| J121 | Written withdrawal of request for trial |